PD Dr. Thomas Kündig

Fakultäten » Medizinische Fakultät » Dermatologische Klinik » PD Dr. Thomas Kündig

Current research projects

Project leader	Project title
Kündig	Regulation of surface and secreted IL-1a
	Role of IL-1a in cancer progression
	Antihistamines as immunosuppressants
Kündig Johansen Senti	Immunotherapy using encapsulated allergens
Kündig Senti	Epicutaneous Allergen Immunotherapy: pilot trial
	Epicutaneous Allergen Immunotherapy: dose finding study

Completed research projects

Project leader	Project title
Kündig	Antihistamines and Immunotherapy
	The effects of antihistamines on bacterial and viral infection
	Antihistamines as Immunosuppressive Agents in Organ Transplantation, Diabetes and Rheumatoid Diseases
	Effects of Antihistamines on Leukocyte Functions in Humans
	Antihistamines in cutaneous T cell lymphoma
	VLP based melanoma vaccine
	Evaluation of HPBCD as an antiviral agent in HSV
	Use of microneedle chips for allergen specific immunotherapy
	Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Rhinoconjunctivitis
Kündig Döbbeling	Use of H1- and of H2-Receptor Antagonists in T Cell Lymphoma
Kündig Dummer	Virus like particles to induce specific cytotoxic T cell responses in melanoma patients
Kündig Johansen	Use of Degradable Polymeric Particles to Enhance Vaccination
	Animal models of contact hypersensitivity
	Micro- and nanoparticles in allergen-specific immunoterhapy
Kündig Senti	Enhancing Allergen Specific Immunotherapy by Intralymphatic Administration in Grass Pollen Allergy
	Use of Modified Recombinant Allergens in Specific Immunotherapy
	Phase I/II Clinical Trial to Evaluate Safety, Tolerability and Clinical Efficacy of a Modified Recombinant Cat Hair Allergen in Allergic Patients
	Establishing a skin test to evaluate the clinical efficacy of allergen specific immunotherapy
	Epicutaneous Allergen Immunotherapy: skin preparation study
Kündig Senti Bachmann	Use of Virus Like Particles to Enhance Immunotherapy with Dust Mite Allergens
Kündig Senti Bachmann Bachmann	Use of Virus Like Particles to Enhance Immunotherapy with Grass Pollen